BPC-157 Accelerated Chemical Burn Healing in Rats by Promoting New Blood Vessel Growth

In vivo: Alkali burns were created on the skin of Sprague-Dawley rats, and BPC-157 was applied topically. Wound closure was monitored, and skin sections were examined histologically with H&E and Masson staining at day 18. In vitro: Human umbilical vein endothelial cells (HUVECs) were treated with BPC-157 and assessed for proliferation (MTT assay, cell cycle analysis), migration (Transwell and wound healing assays), VEGF expression, tube formation, and ERK1/2 pathway activation.

Chemical burns are common industrial and household injuries with limited treatment options. BPC-157's ability to promote both tissue regeneration and new blood vessel formation through a defined signaling pathway provides mechanistic support for its wound healing potential. Understanding the ERK1/2 mechanism also opens avenues for optimizing peptide-based wound therapies.

BPC-157 has been studied extensively in animal models for tissue healing across multiple organ systems. This study adds mechanistic depth by identifying the ERK1/2-VEGF-angiogenesis axis as a key pathway. The topical application route is particularly relevant for clinical translation, as it avoids systemic exposure. However, like most BPC-157 research, human clinical trials remain absent.

This is an animal study in rats — results may not translate directly to human chemical burns. The study doesn't report specific BPC-157 doses or concentrations used topically. Only one time point (day 18) was examined histologically, so the full healing trajectory is unclear. No human clinical trial data exists for BPC-157 in burn treatment.